In the pharmaceutical industry, a robust quality system is essential to ensure patient safety, product efficacy, and regulatory compliance. Within this framework, audits play a critical role by verifying that processes, procedures, and activities comply with applicable requirements while identifying opportunities for improvement.
What are pharmaceutical quality audits?
An audit is a systematic, independent, and documented assessment used to verify compliance with internal procedures, industry standards, and regulatory requirements. In the pharmaceutical sector, audits may involve company processes, suppliers, contract manufacturers, laboratories, distributors, or other partners within the supply chain.
Audits can be internal, external, or conducted by regulatory authorities as part of official inspections. In all cases, the objective is to assess compliance with applicable Good Practices, such as GMP, GDP, GVP, and, more broadly, GxP requirements.
Why are audits important?
Audits perform both a preventive and strategic function. They help identify non-conformities, organizational weaknesses, and deviations from established procedures before they develop into more significant issues affecting products or patients.
Even seemingly minor findings, such as incomplete records or outdated procedures, can have important consequences. Therefore, audits help organizations maintain control over their processes, strengthen traceability, and prepare for regulatory inspections.
In addition, audits contribute to continuous improvement by providing objective evidence of how effectively the quality system is being implemented and maintained.
How does an audit work and what do auditors verify?
An audit typically follows several key stages:
- Planning: defining the scope, objectives, processes involved, audit team, and schedule.
- Preparation: reviewing available documentation, including procedures, records, previous audits, deviations, complaints, changes, and CAPAs.
- Execution: collecting evidence through interviews, direct observation of activities, and document review to verify the effective implementation of procedures.
- Closing meeting and reporting: discussing observations and documenting findings in a final audit report.
- Follow-up: verifying the implementation and effectiveness of agreed corrective and preventive actions.
During the audit, auditors assess multiple aspects of the pharmaceutical quality system, including organizational structure, roles and responsibilities, resource allocation, personnel training, and procedural compliance.
Particular attention is given to documentation and data integrity, ensuring that data are reliable, complete, accurate, and traceable. A fundamental principle of pharmaceutical quality systems remains: what is not documented cannot be demonstrated.
Auditors also review deviations, complaints, changes, CAPAs, manufacturing activities, packaging operations, quality control processes, cleaning procedures, equipment qualification, computerized systems, storage conditions, and distribution activities.
Non-conformities and their classification
When deviations from requirements are identified, they are classified as non-conformities or observations based on their severity, associated risk, and potential impact on product quality, process performance, and patient safety.
This classification helps establish priorities and determine the urgency of corrective actions.
Minor non-conformities typically involve limited deviations, often documentation-related, that do not directly affect product quality or patient safety but still require correction.
Major non-conformities indicate more significant or systemic deficiencies, such as procedures that are not consistently followed or deviations that have not been appropriately managed. These issues may have an impact on product quality or patient safety.
Critical non-conformities are the most serious findings because they may present an immediate or significant risk to patient safety, medicinal product quality, or regulatory compliance.
Consequently, classification is much more than an administrative step. It determines timelines, responsibilities, and the depth of root cause investigations. The goal is not only to identify errors but also to establish corrective and preventive actions that are proportionate to the associated risks and effective over the long term.
Conclusion
Audits should not be viewed solely as inspection activities but as opportunities to strengthen quality culture and improve organizational processes.
A well-executed audit promotes transparency, collaboration, and awareness throughout the organization. At the same time, it helps identify risks, prevent future issues, and reinforce the confidence of regulatory authorities, business partners, and patients.
References
- European Commission – EudraLex Volume 4 (EU GMP Guidelines)
- European Medicines Agency (EMA) – Good Pharmacovigilance Practices (GVP), Module IV: Pharmacovigilance Audits
- European Commission – Good Distribution Practice (GDP) of medicinal products for human use (2013/C 343/01)
- World Health Organization (WHO) – Good practices for pharmaceutical quality control laboratories
- S. Food and Drug Administration (FDA) – Quality Systems Approach to Pharmaceutical CGMP Regulations